In rodent models, BPC-157 demonstrated a wide therapeutic index with no observed hepatotoxicity, nephrotoxicity, or neurotoxicity across multiple dosing regimens. Sikiric et al., Regenerative Pharmacology Reported Side Effects (Rare) While side effects are rare, some users report: Peptides like BPC-157 generally exhibit low immunogenicity and low systemic toxicity, though user-specific variables such as injection technique or gut sensitivity may influence short-term side effects. [Clinical Peptide Society Review, 2021] Is BPC-157 Safe for Long-Term Use
The September cluster is weighted towards rare disease filings where randomisation is difficult and natural history comparisons do much of the work, which is precisely the territory these disputes have concerned
Additionally, they exhibit anti-proliferative and anti-apoptotic effects through pathways like HGF/SF-Met signaling, the MAPK pathway, and the PI3K-Akt pathway
The FDA decision on BPC-157 The FDA placed BPC-157 on its list of Category 2 bulk drug substances
